Some of the worlds most widely used drugs, e.g. acetylsalicylic acid, penicillins, omeprazole, clopidogrel, etc, are all based on covalent inhibition of the target enzyme. However, few drugs are designed to be covalent, and the pharmaceutical industry is still cautious for this mode-of-action due to an inherent risk of late stage idiosyncratic toxicology. In this workshop we gather industrial and academic experts to review state-of-the-art and shed some light on this perplexity. Please, take the chance to discuss your own project with the speakers during the day.
Registration and Coffee
Covalent Kinase Inhibitor Drugs: The Future is Already Here
Tjeerd Barf, Acerta Pharma, Netherlands
Safety first: Covalent inhibitors from a safety perspective
Mickael Mogemark, Astra Zeneca, Sweden
Reversible covalent inhibitors of cathepsins
Lourdes Salvador Oden, Medivir, Sweden
Utilizing a covalent mechanism for target identification and development of a STAT3 inhibitor prodrug
Martin Johansson, Glactone Pharma Development, Sweden
Bioanalysis of a soft and highly reactive electrophile
Lars Hagberg, Aprea, Sweden
Thank you for helping us improve by filling out this brief evaluation form.Please select a valid form
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.